Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a ...

Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the ...

・The analyst noted that Ocugen has three clinical stage programs in rare and non-rare retinal diseases including OCU400, OCU410ST and OCU410. ・According to data from Koyfin, all six of the six ...

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...

Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no ...

Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X-TOLE2 study of azetukalner for focal onset seizures with top line data readout in early 2026; ...

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy ...

Roivant Sciences Ltd. (NASDAQ: ROIV) set out its long-term vision on Tuesday during its Investor Day, outlining accelerated timelines and expanded commercial ambitions across several late-stage ...

Find out the orgs offering cash investments, mentorship and spaces to collaborate with other entrepreneurs in the region.